-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
KL-A167 is a fully humanized monoclonal antibody that targets programmed cell death ligand 1 (PD-L1
This is a multicenter, single-group Phase 2 trial, carried out simultaneously in 42 hospitals in mainland China, recruiting patients with non-keratinized R/M NPC who have failed after previous ≥ 2-line chemotherapy with a clear diagnosis of histology, and treated with KL-A167 900 mg (1 time/2 weeks) until disease progression, intolerable toxicity or withdrawal trial
Between 26 February 2019 and 13 January 2021, a total of 153 patients were treated
Baseline low plasma EBV DNA load is associated
Together, the findings demonstrate the promising efficacy and controllable safety of
Original Source:
Yuankai Shi, et al.